Cost-Effectiveness of Adding SGLT2 Inhibitors to Standard Treatment for Heart Failure With Reduced Ejection Fraction Patients in China

Objective: To evaluate the economics and effectiveness of adding dapagliflozin or empagliflozin to the standard treatment for heart failure (HF) for patients with reduced ejection fraction (HFrEF) in China. Methods: A Markov model was developed to project the clinical and economic outcomes of adding...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Yaohui, Zheng, Rujie, Sang, Haiqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8631914/
https://www.ncbi.nlm.nih.gov/pubmed/34858172
http://dx.doi.org/10.3389/fphar.2021.733681

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8631914/
https://www.ncbi.nlm.nih.gov/pubmed/34858172
http://dx.doi.org/10.3389/fphar.2021.733681

Ejemplares similares